- Recent Funding
- Investors
- FemHealth Ventures
FemHealth Ventures portfolio
FemHealth Ventures has 2 portfolio companies on record at Recent Funding. Its most recent investment on record is Reunion Neuroscience's $133M Series A round in September 2025, alongside Plaisance Capital Management, Palo Santo Fund, Novo Holdings and 3 others. By category, its portfolio leans toward Health and bio (2).
What FemHealth Ventures invests in
- Health and bio · 2 · 100%
How FemHealth Ventures invests
| Stage | Deals | Capital in rounds |
|---|---|---|
| Series A | 1 100% | $133M |
Share is of the 1 round on Recent Funding that name FemHealth Ventures. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.
FemHealth Ventures portfolio companies
RReunion Neuroscience$133MSeries A · Sep 2025
RRejonibacker
| Company | Round with FemHealth Ventures | Total raised | Latest raise |
|---|---|---|---|
Health and bio |
Series A · $133M | $133M | Sep 16, 2025 Series A |
Health and bio |
backer | $25M | Jun 16, 2026 round |
Most frequent co-investors
NNovo Holdings1 shared round · last Sep 16, 2025
MMPM Capital1 shared round · last Sep 16, 2025
PPlaisance Capital Management1 shared round · last Sep 16, 2025
PPalo Santo Fund1 shared round · last Sep 16, 2025
MMitsui Global Investment1 shared round · last Sep 16, 2025
AArkin Bio Ventures1 shared round · last Sep 16, 2025
Similar investors
CCalm/Storm VC2 companies · 2 deals in 12 mo
HHuatai Zijin Investment2 companies · 2 deals in 12 mo
IIIMA Ventures2 companies · 2 deals in 12 mo
SSound Bioventures2 companies · 2 deals in 12 mo
TTenmile2 companies · 2 deals in 12 mo
TThe FSE Group2 companies · 2 deals in 12 mo
Investors whose portfolios on Recent Funding center on the same category (Health and bio).
Portfolio companies are the companies on Recent Funding with a round that lists FemHealth Ventures, which is a subset of its real portfolio. API: /api/v1/investors/femhealth-ventures (get a free API key). More: the most active VC firms and new venture capital funds.